Subscribe
Nathan Devery / Shutterstock.com
22 April 2025NewsEuropeSarah Speight

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug

Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

More on this story

Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025   The licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into the high-profile portfolio’s future, finds Marisa Woutersen.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

More features

In vivo cell therapy: A world beyond ex vivo engineering
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart-Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist